Grand Pharmaceutical Group Ltd banner
G

Grand Pharmaceutical Group Ltd
HKEX:512

Watchlist Manager
Grand Pharmaceutical Group Ltd
HKEX:512
Watchlist
Price: 6.4 HKD -1.08% Market Closed
Market Cap: HK$22.7B

Grand Pharmaceutical Group Ltd
Income from Continuing Operations

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Grand Pharmaceutical Group Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
G
Grand Pharmaceutical Group Ltd
HKEX:512
Income from Continuing Operations
HK$1.2B
CAGR 3-Years
-16%
CAGR 5-Years
-7%
CAGR 10-Years
20%
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
Income from Continuing Operations
-$3.6m
CAGR 3-Years
22%
CAGR 5-Years
-35%
CAGR 10-Years
N/A
U
United Laboratories International Holdings Ltd
HKEX:3933
Income from Continuing Operations
¥2.1B
CAGR 3-Years
10%
CAGR 5-Years
24%
CAGR 10-Years
36%
Sino Biopharmaceutical Ltd
HKEX:1177
Income from Continuing Operations
¥5.3B
CAGR 3-Years
6%
CAGR 5-Years
4%
CAGR 10-Years
8%
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Income from Continuing Operations
HK$9.7B
CAGR 3-Years
13%
CAGR 5-Years
13%
CAGR 10-Years
N/A
H
HUTCHMED (China) Ltd
HKEX:13
Income from Continuing Operations
$457.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
46%
No Stocks Found

Grand Pharmaceutical Group Ltd
Glance View

Market Cap
22.7B HKD
Industry
Pharmaceuticals

Grand Pharmaceutical Group Ltd. stands as a significant player in the pharmaceutical industry, strategically positioned in the bustling hub of the Asia-Pacific region. Founded with a vision to harness scientific innovation for healing, the company has diligently expanded its reach and capabilities over the years. Grand Pharma is meticulously structured around three core segments: Medicine and Healthcare, Biopharmaceutical Manufacturing, and Medical Devices. In the Medicine and Healthcare segment, it advances an extensive portfolio of both proprietary and generic drugs. This segment alone accounts for a substantial portion of its revenue, capitalizing on its adeptness in research and development to maintain a robust pipeline of products. By continuously innovating and seeking to meet unmet medical needs, Grand Pharma sustains its competitive edge in the market. Their Biopharmaceutical Manufacturing segment shines brightly as a beacon of future growth, showcasing their commitment to biotechnology. Here, Grand Pharmaceutical leverages cutting-edge biotechnologies to develop therapies targeting a range of complex diseases. This segment is noted for its high-margin potential, driven by the increasing global demand for biologics. Furthermore, their Medical Devices segment complements the pharmaceutical operations by delivering state-of-the-art products in areas such as cardiovascular health and surgical equipment. By maintaining a balanced and diversified portfolio across these business areas, Grand Pharmaceutical effectively mitigates risks and capitalizes on emerging trends in global healthcare markets. Through astute strategic planning and an unwavering commitment to quality and innovation, the company fortifies its position as a leader in the field, continually reinvesting its profits to further enhance its offerings and broaden its impact.

Intrinsic Value
5.88 HKD
Overvaluation 8%
Intrinsic Value
Price HK$6.4
G

See Also

What is Grand Pharmaceutical Group Ltd's Income from Continuing Operations?
Income from Continuing Operations
1.2B HKD

Based on the financial report for Dec 31, 2025, Grand Pharmaceutical Group Ltd's Income from Continuing Operations amounts to 1.2B HKD.

What is Grand Pharmaceutical Group Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
20%

Over the last year, the Income from Continuing Operations growth was -50%. The average annual Income from Continuing Operations growth rates for Grand Pharmaceutical Group Ltd have been -16% over the past three years , -7% over the past five years , and 20% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett